Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Free Dating
Ñompany Maksim-LLC. Ýëåêòðîïðèâîäû. Made and sell.
Popular Articles

cure me

ATS Medical Announces FDA Clearance And First Implant Of New ATS Simulus Semi-Rigid Annuloplasty Band
ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, announced FDA clearance and the first implant of the ATS Simulus(R) Semi-Rigid Annuloplasty Band. The Simulus Semi-Rigid Annuloplasty Band was developed through the Company"s collaboration with Genesee BioMedical and represents the latest addition to the expanding portfolio of valve repair products.
Polygraphy
Medicare Analysis Finds Too Many Needless Deaths At Hospitals
A new Medicare analysis by the Centers for Medicare and Medicaid Services found a "double failure" at U.S. hospitals. Its release comes as the White House and Congress seek ways to reward quality over quantity of care in health care reform. USA Today reports that "Too many people die needlessly at U.S. hospitals, according to a sweeping new Medicare analysis showing wide variation in death rates between the best hospitals and the worst. The analysis examined death rates for heart attacks, heart failure and pneumonia at more than 4,600 hospitals across the USA. At 5.9% of hospitals, patients with pneumonia died at rates significantly higher than the national average. With heart failure, 3.4% of hospitals had death rates higher than the average, and 1.2% of hospitals were higher when it came to heart attack. Researchers also found that the majority of U.S. hospitals operate the equivalent of revolving doors for their patients. One of every four heart failure patients and slightly less than one in five heart attack and pneumonia patients land back in the hospital within 30 days, data show."
News of the day
National Organization For Rare Disorders To Honor Rare Disease Pioneers
The National Organization for Rare Disorders (NORD) will honor a senior U.S. Senator, a top Administration official, a cutting-edge television network, and several pioneering companies developing treatments for rare diseases at the 2009 NORD Gala at the National Press Club in Washington, DC, on Thursday, May 14.
Cardiovascular

Researchers Identify New Method To Selectively Kill Metastatic Melanoma Cells

An international team of researchers has identified a new method for selectively killing metastatic melanoma cells, which may lead to new areas for drug development in melanoma - a cancer that is highly resistant to current treatment strategies. Researchers from Virginia Commonwealth University, in collaboration with a team of researchers led by Maria S. Soengas, Ph.D., with the Spanish National Cancer Research Center in Madrid, Spain, found that activation of a specific molecular pathway triggers melanoma cells to begin a process of self-destruction - through self-digestion and programmed cell death. The study is published in the August 4 print issue of the journal Cancer Cell. "The present research provides a path that could lead with further studies and a phase I clinical trial for safety to the development of a strategy that reenergizes the immune system to destroy this highly aggressive cancer," said lead investigator at VCU, Paul B. Fisher, M.Ph., Ph.D., the first incumbent of the Thelma Newmeyer Corman Endowed Chair in Cancer Research with the VCU Massey Cancer Center. According to Fisher, the pathway that is activated involves the melanoma differentiation associated gene-5, or mda-5, a gene initially cloned in Fisher"s laboratory, that activates a protein called NOXA that is involved with programmed cell death. This series of chemical reactions results in induction of a cell-killing process involving self-digestion that leads to programmed cell death specifically in melanoma cells. Fisher said that mda-5 is a key regulator of innate immunity that induces interferon beta production limiting replication of specific pathogenic viruses. This work was supported by grants from the National Institutes of Health, the Spanish Ministry of Science and Innovation, the Spanish Association Against Cancer and the Spanish National Cancer Research Center. The project team in Spain was led by Soengas, with the Melanoma Laboratory, Molecular Pathology Program, Spanish National Cancer Research Center, Madrid, Spain. Fisher, who also is professor and chair of the Department of Human and Molecular Genetics, and director of the VCU Institute of Molecular Medicine in the VCU School of Medicine, lead the investigative team at VCU which included Paola M. Barral, Ph.D., assistant professor in the Department of Human and Molecular Genetics; and Rupesh Dash, Ph.D., postdoctoral research scientist, in the Department of Human and Molecular Genetics, and the VCU Institute of Molecular Medicine. Sathya Achia Abraham Virginia Commonwealth University


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009